Erenumab-aooe 70MG/ML autoinjector 1ML erenumab-aooe 140MG/ML autoinjector 1ML

Ended Indefinite Delivery Contract Awarded Last action

Contract number
36E79720D0006
Awardee
Awarding agency
Task orders
3 $88,022 obligated

Award facts

Opportunity
Combined order value
$88,022 Current and potential, with all options
Last date to order 100% complete
IDV ceiling <1% used
$58,968,306.00
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The federal contract IDV awarded to Amgen USA Inc., a division of the biotechnology company Amgen Inc., is primarily focused on supplying calcitonin gene-related peptide (CGRP) agents to the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The original solicitation, RFP 36E79719R0025 issued by the VA National Acquisition Center, sought a one-year contract with four one-year option periods to provide Erenumab-aooe, Fremanezumab-vfrm, and Galcanezumab-gnlm in various dosages and package sizes, with an estimated annual usage of 86,148 doses for each item.

Under this IDV contract (36E79720D0006) with a ceiling value of $58.97 million, Amgen has received delivery orders to supply influenza vaccines to the VA, BOP, and other federal agencies. For example, Amgen provided AFLURIA QUADRIVALENT 0.5ML single-dose, pre-filled syringes to the VA's Veterans Integrated Service Network 5 and flu shots to staff at the Federal Correctional Institution Terminal Island operated by the BOP. These task orders demonstrate Amgen's role in supporting federal healthcare initiatives by delivering critical pharmaceutical products to various government customers.

Task orders

Transactions

Action Obligated Date
Add Subcontract Plan P00018 · Incorporate 2025 small business subcontracting plan into contract. $0
Other Administrative Action P00017 · Incorporate 2025 federal ceiling prices into contract. No changes to national contract prices. $0
Supplemental Agreement for work within scope P00016 · This modification is issued to update the terms of the CRF payment remittal and submission of quarterly sales reports $0
Exercise an Option P00015 · This modification is issued to exercise the fourth option year for calcitonin gene-related peptide $0
Add Subcontract Plan P00014 · This modification is being issued to incorporate amgen USA INC. Subcontracting plan effective for the period of january 1, 2024 through december 31, 2024. $0
Other Administrative Action P00013 · This modification is issued to incorporate 2024 federal ceiling prices under national contract 36E79720D0006 $0
Other Administrative Action P00012 · Title II of the drug quality and security act (dqsa), known as the dscsa, applies to all drug products, with the exception of those listed on the dscsa… $0
Exercise an Option P00011 · This modification is issued to exercise the third option year for calcitonin gene-related peptide $0
Other Administrative Action P00010 · This modification is issued to incorporate amgen's 2023 federal ceiling prices under national contract 36E79720D0006 $0
Add Subcontract Plan P00009 · This modification is being issued to incorporate amgen USA INC. Subcontracting plan effective for the period of january 1, 2023 - december 31, 2023. $0
Exercise an Option P00007 · Exercise option year two $0
Add Subcontract Plan P00008 · 2022 subcontracting plan $0
Other Administrative Action P00006 · Public law 102-585 $0
Other Administrative Action P00005 · Point of contact change $0
Add Subcontract Plan P00004 · 52.219-9 small business subcontracting plan $0
Exercise an Option P00003 · Exercise the first option year with amgen USA INC. On contract 36E79720D0006 $0
Other Administrative Action P00002 · Administrative point of contact change $0
Other Administrative Action P00001 · Public law 102-585 erenumab-aooe 70MG/ML autoinjector 1ML erenumab-aooe 140MG/ML autoinjector 1ML $0
Original award $0
Show all 19

Quick answers

Who was awarded contract 36E79720D0006?

36E79720D0006 was awarded to Amgen USA Inc. by National Acquisition Center (Headquarters) on February 26, 2020.

How much is contract 36E79720D0006 worth?

Orders under 36E79720D0006 have obligated $88,022. 36E79720D0006's own ceiling is $58,968,306.

How many orders have been placed under contract 36E79720D0006?

3 orders have been placed under 36E79720D0006, the latest on April 9, 2021.

Who can order from contract 36E79720D0006?

36E79720D0006 is a single award indefinite delivery contract.

Was contract 36E79720D0006 competed?

The extent of competition for 36E79720D0006 was full and open competition. The government received 2 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV